Bromisovalum
A brominated sedative and hypnotic agent that was used historically to treat anxiety and insomnia. It belongs to the bromide-containing compounds that were widely used before benzodiazepines became available. It is no longer in clinical use due to the risk of bromism with prolonged administration and the availability of safer alternatives.
Masse moléculaire
223,0700 g/mol
LogP
1,10
TPSA
72,20 Ų
Règle des 5 de Lipinski
Conforme
Mécanisme d'action
Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, …
Structure 2D
Cite this structure
Embed this structure
SMILES
CC(C)C(Br)C(=O)NC(N)=O
InChI
InChI=1S/C6H11BrN2O2/c1-3(2)4(7)5(10)9-6(8)11/h3-4H,1-2H3,(H3,8,9,10,11)
Molecular Formula
C6H11BrN2O2
HBD / HBA
2 / 2
Liaisons Rotatives
2
Atomes Lourds
11
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
A brominated sedative and hypnotic agent that was used historically to treat anxiety and insomnia. It belongs to the bromide-containing compounds that were widely used before benzodiazepines became available. It is no longer in clinical use due to the risk of bromism with prolonged administration and the availability of safer alternatives.
Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.
Yes, Bromisovalum is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1515611. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 2447. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="bromisovalum"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/bromisovalum/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/bromisovalum/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/bromisovalum/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="bromisovalum"></drugfyi-drug>